Nobilis Therapeutics Signs License Agreement with Harvard University


SAN DIEGO, CA-March 28, 2016 – Nobilis Therapeutics, Inc. announced today entry into an exclusive agreement with Harvard University’s Partners Healthcare to license intellectual property surrounding the use of noble gas-containing mixtures as a treatment for Post-Traumatic Stress Disorder (PTSD). The agreement gives Nobilis Therapeutics the rights to the treatment of PTSD as well as of other psychiatric disorders.

The use of Noble gas-containing mixtures to treat PTSD was pioneered by researchers at Harvard-affiliated McLean Hospital, including Dr. Edward Meloni, PhD, an Assistant Professor of Psychiatry. Dr. Meloni’s recent animal study had decisively demonstrated a significant reduction in fear symptoms after exposure to noble gas-containing gas mixture1.

Subscribe to get the latest news